Pfenex And Alvogen May Face Delay In Teriparatide Equivalence Rating

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

Pfenex remains hopeful of receiving US approval for its teriparatide hybrid rival to Eli Lilly’s Forteo in October this year. But commercial partner Alvogen may have to wait for a therapeutic equivalence rating to the osteoporosis original.

Delayed
Obtaining a therapeutic equivalence rating for Pfenex' hybrid teriparatide device in the US could be delayed by a lack of FDA feedback on a study protocol • Source: Shutterstock

Pfenex and commercial partner Alvogen could face a delay in obtaining an ‘A’ therapeutic equivalence rating for the 505(b)(2) hybrid rival to Eli Lilly’s Forteo teriparatide brand for which they hope to obtain US approval in early October. The US Food and Drug Administration recently told Pfenex that it might be premature to comment on the firm’s protocol for a comparative human factors study for the drug-device combination until the label details for the PF708 teriparatide candidate have been agreed, which may be close to the osteoporosis treatment’s Prescription Drug User Fee Act target date of 7 October 2019.

Stressing that it was discussing the situation with the agency, Pfenex admitted: “Depending on the outcome, it may delay the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

  • Neuraxpharm Enters Japanese Market 1

     
    • By David Wallace

    Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

  • Hyloris Sets Out Plans To Expand Its Pipeline

     
    • By Akriti Seth

    After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

  • Awards Offers Two Weeks Of Online Networking

     
    • By David Wallace

    From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

  • Hyloris And Purna Strike Value-Added Development Deal

     
    • By David Wallace

    Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.